Abiopharma

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

NewAmsterdam Pharma Announces Positive ToplineAlzheimer’s Disease Data from BROADWAY Clinical Trial

Stepan Company Announces Appointment of New Director

New Form 8-K - Genprex, Inc. Filed: 2025-06-09 AccNo: 0001437749-25-019767 Size: 160 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits

New Form 8-K - Lyra Therapeutics, Inc. Filed: 2025-06-09 AccNo: 0001193125-25-137418 Size: 3 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 424B5 - Venus Concept Inc. Filed: 2025-06-09 AccNo: 0001140361-25-021861 Size: 637 KB

Sagimet Biosciences to Host Virtual KOL Event, “ANew Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to SevereAcne” on June 16, 2025

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

New Form 6-K - PORTAGE BIOTECH INC. Filed: 2025-06-09 AccNo: 0001171843-25-003779 Size: 69 KB

COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

New Form 8-K - Keros Therapeutics, Inc. Filed: 2025-06-09 AccNo: 0001664710-25-000057 Size: 232 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits